Your browser doesn't support javascript.
loading
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Bhatty, Minny; Kato, Shumei; Piha-Paul, Sarina A; Naing, Aung; Subbiah, Vivek; Huang, Helen J; Karp, Daniel D; Tsimberidou, Apostolia M; Zinner, Ralph G; Hwu, Wen-Jen; Javle, Milind; Patel, Sapna P; Hu, Mimi I; Varadhachary, Gauri R; Conley, Anthony P; Ramzanali, Nishma M; Holley, Veronica R; Kurzrock, Razelle; Meric-Bernstam, Funda; Kwang Chae, Young; Kim, Kevin B; Falchook, Gerald S; Janku, Filip.
  • Bhatty M; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kato S; Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, California.
  • Piha-Paul SA; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, California.
  • Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang HJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zinner RG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hwu WJ; Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Javle M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patel SP; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu MI; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Varadhachary GR; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Conley AP; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ramzanali NM; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Holley VR; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Meric-Bernstam F; Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, California.
  • Kwang Chae Y; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, California.
  • Kim KB; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Falchook GS; Developmental Therapeutics, Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Janku F; Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Cancer ; 125(3): 463-472, 2019 02 01.
Article en En | MEDLINE | ID: mdl-30383888
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Paclitaxel / Vemurafenib / Melanoma / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatino / Paclitaxel / Vemurafenib / Melanoma / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article